Complete the 2-Dose Shingrix Series Now
The patient should receive the second dose of Shingrix immediately to complete the 2-dose series, regardless of the 10-year interval since the first dose. There is no maximum interval between doses, and completing the series is critical for optimal protection against herpes zoster.
Rationale for Completing the Series
The FDA label for Shingrix clearly establishes that the vaccine is administered as a 2-dose series, with doses given 2-6 months apart 1. However, there is no specified maximum interval beyond which the series must be restarted. The patient should simply receive the second dose now to complete the primary vaccination series.
Evidence Supporting Series Completion
Real-world effectiveness data strongly supports the importance of completing both doses:
Two-dose effectiveness is substantially higher than one dose: Real-world studies demonstrate 2-dose vaccine effectiveness of 76% 2 and 70.1% 3, compared to only 56.9% for a single dose 3
Single-dose protection wanes rapidly: After one dose only, effectiveness drops from 70% in the first year to 45% in the second year and remains around 48-52% thereafter 2. This means your patient likely has minimal protection after 10 years with only one dose.
Two-dose protection is durable: After completing both doses, effectiveness remains stable at 79% in year one, 75% in year two, and 73% in years three and four 2, with minimal waning over 4 years of follow-up
Practical Considerations
Timing of Second Dose
While the recommended interval is 2-6 months 1, delayed second doses beyond 6 months do not impair effectiveness 3. The FDA label notes that safety and immunogenicity were similar when administered on a 0- and 2-month or 0- and 6-month schedule 1. Taiwan guidelines suggest a minimal 8-week interval when switching between zoster vaccines, though the optimal interval is unknown 4.
No Need to Restart the Series
Unlike some vaccine series, there is no evidence requiring the series to be restarted after a prolonged interval. The patient's first dose from 10 years ago should count toward the 2-dose series.
Expected Side Effects
The patient should be counseled that local and systemic reactions are common and actually more frequent after the second dose 1:
- Headache and shivering occur more frequently after dose 2 (28% and 21%) compared to dose 1 (24% and 14%)
- Grade 3 reactions (preventing normal activity) are also more common after dose 2
- Most reactions last 2-3 days and are self-limited
Clinical Bottom Line
Administer the second dose of Shingrix now without repeating the first dose. The 10-year interval, while far beyond the recommended 2-6 months, does not invalidate the first dose or require restarting the series. Completing the 2-dose regimen is essential, as single-dose protection is inadequate and wanes substantially over time.